The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma rec
- PDF / 1,313,923 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 63 Downloads / 240 Views
RESEARCH ARTICLE
Open Access
The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies Chiao-En Wu1,2,3* , Chan-Keng Yang1,2,3, Meng-Ting Peng1,2,3, Pei-Wei Huang1,2,3, Ching-Fu Chang1,2,3, Kun-Yun Yeh3,4,5, Chun-Bing Chen3,5,6, Chih-Liang Wang3,5,7, Chao-Wei Hsu3,5,8, I-Wen Chen3,5,9, Cheng-Tao Lin3,5,10, Shir-Hwa Ueng3,5,11, Gigin Lin3,5,12, Yu-Fen Lin3,13, Chi-Yuan Cheng3,5,14 and John Wen-Cheng Chang1,2,3*
Abstract Background: The association between immune-related adverse events (irAEs) and survival outcomes in patients with advanced melanoma receiving therapy with immune checkpoint inhibitors (ICIs) has not been well established, particularly in Asian melanoma. Methods: We retrospectively reviewed 49 melanoma patients undergoing therapy with ICIs (anti-PD-1 monotherapy), and analyzed the correlation between irAEs and clinical outcomes including progression-free survival (PFS) and overall survival (OS). Results: Overall, the patients who experienced grade 1–2 irAEs had longer PFS (median PFS, 4.6 vs. 2.5 months; HR, 0.52; 95% CI: 0.27–0.98; p = 0.042) and OS (median OS, 15.2 vs. 5.7 months; HR, 0.50; 95% CI: 0.24–1.02; p = 0.058) than the patients who did not experience irAEs. Regarding the type of irAE, the patients with either skin/vitiligo or endocrine irAEs showed better PFS (median PFS, 6.1 vs. 2.7 months; HR, 0.40, 95% CI: 0.21–0.74; p = 0.003) and OS (median OS, 18.7 vs. 4.5 months; HR, 0.34, 95% CI: 0.17–0.69, p = 0.003) than patients without any of these irAEs. Conclusions: Melanoma patients undergoing anti-PD-1 monotherapy and experiencing mild-to-moderate irAEs (grade 1–2), particularly skin (vitiligo)/endocrine irAEs had favorable survival outcomes. Therefore, the association between irAEs and the clinical outcomes in melanoma patients undergoing anti-PD-1 ICIs may be severity and type dependent. Keywords: Immune checkpoint inhibitors, irAE, Skin toxicity, Vitiligo, Endocrine, Melanoma, PD-1
* Correspondence: [email protected]; [email protected] 1 Division of Haematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan Full list of author information is available at the end of the article
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To
Data Loading...
